224 related articles for article (PubMed ID: 28255749)
1. Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas.
Yao X; Gao H; Li C; Wu L; Bai J; Wang J; Li Y; Zhang Y
J Neurooncol; 2017 Apr; 132(2):199-206. PubMed ID: 28255749
[TBL] [Abstract][Full Text] [Related]
2. Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth.
Šteňo A; Bocko J; Rychlý B; Chorváth M; Celec P; Fabian M; Belan V; Šteňo J
Acta Neurochir (Wien); 2014 Mar; 156(3):451-61; discussion 461. PubMed ID: 24452592
[TBL] [Abstract][Full Text] [Related]
3. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
Ramírez C; Cheng S; Vargas G; Asa SL; Ezzat S; González B; Cabrera L; Guinto G; Mercado M
J Clin Endocrinol Metab; 2012 May; 97(5):1745-51. PubMed ID: 22419713
[TBL] [Abstract][Full Text] [Related]
4. Association of TGF-β1 and WIF1 Expression with 36 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas: A High-Throughput Tissue Microarrays Immunohistochemical Study.
Zhu H; Yao X; Wu L; Li C; Bai J; Gao H; Ji H; Zhang Y
World Neurosurg; 2018 Nov; 119():e23-e31. PubMed ID: 29966778
[TBL] [Abstract][Full Text] [Related]
5. PTTG overexpression in non-functioning pituitary adenomas: Correlation with invasiveness, female gender and younger age.
Trott G; Ongaratti BR; de Oliveira Silva CB; Abech GD; Haag T; Rech CGSL; Ferreira NP; da Costa Oliveira M; Pereira-Lima JFS
Ann Diagn Pathol; 2019 Aug; 41():83-89. PubMed ID: 31154064
[TBL] [Abstract][Full Text] [Related]
6. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
7. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile.
Batista RL; Trarbach EB; Marques MD; Cescato VA; da Silva GO; Herkenhoff CGB; Cunha-Neto MB; Musolino NR
World Neurosurg; 2018 Dec; 120():e241-e246. PubMed ID: 30138730
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas.
Wang EL; Qian ZR; Rahman MM; Yoshimoto K; Yamada S; Kudo E; Sano T
Histopathology; 2010 Mar; 56(4):501-9. PubMed ID: 20459557
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
10. PTTG and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Przegl Lek; 2016; 73(2):53-8. PubMed ID: 27197423
[TBL] [Abstract][Full Text] [Related]
11. Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.
Butz H; Németh K; Czenke D; Likó I; Czirják S; Zivkovic V; Baghy K; Korbonits M; Kovalszky I; Igaz P; Rácz K; Patócs A
Pathol Oncol Res; 2017 Jul; 23(3):633-641. PubMed ID: 28004354
[TBL] [Abstract][Full Text] [Related]
12. HMGA1-pseudogene expression is induced in human pituitary tumors.
Esposito F; De Martino M; D'Angelo D; Mussnich P; Raverot G; Jaffrain-Rea ML; Fraggetta F; Trouillas J; Fusco A
Cell Cycle; 2015; 14(9):1471-5. PubMed ID: 25894544
[TBL] [Abstract][Full Text] [Related]
13. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas.
Hentschel SJ; McCutcheon lE; Moore W; Durity FA
Can J Neurol Sci; 2003 Aug; 30(3):215-9. PubMed ID: 12945944
[TBL] [Abstract][Full Text] [Related]
14. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
15. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
16. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.
Rishi A; Sharma MC; Sarkar C; Jain D; Singh M; Mahapatra AK; Mehta VS; Das TK
Neurol India; 2010; 58(3):418-23. PubMed ID: 20644271
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and growth fractions of pituitary adenomas.
Yonezawa K; Tamaki N; Kokunai T
Surg Neurol; 1997 Nov; 48(5):494-500. PubMed ID: 9352815
[TBL] [Abstract][Full Text] [Related]
19. Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.
Vieira Neto L; Wildemberg LE; Moraes AB; Colli LM; Kasuki L; Marques NV; Gasparetto EL; de Castro M; Takiya CM; Gadelha MR
Clin Endocrinol (Oxf); 2015 May; 82(5):739-46. PubMed ID: 25418156
[TBL] [Abstract][Full Text] [Related]
20. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
